Atlas Trials

Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria

Clinical trial NCT06865651 · RECRUITING

Trial details

NCT number
NCT06865651
Sponsor
Novartis Pharmaceuticals
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Chronic Urticaria (CU): Chronic Inducible Urticaria (CINDU) and Chronic Spontaneous Urticaria (CSU)
Start date
2025-05-22
Primary completion
2027-08-23
Enrollment
44

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.